BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35399715)

  • 1. Expression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort.
    Zschäbitz S; Erlmeier F; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Mondorf Y; Hartmann A; Ivanyi P; Steffens S
    J Cancer; 2022; 13(6):1706-1712. PubMed ID: 35399715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSMA-Expression Is Highly Associated with Histological Subtypes of Renal Cell Carcinoma: Potential Implications for Theranostic Approaches.
    Bui VN; Unterrainer LM; Brendel M; Kunte SC; Holzgreve A; Allmendinger F; Bartenstein P; Klauschen F; Unterrainer M; Staehler M; Ledderose S
    Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms.
    Baccala A; Sercia L; Li J; Heston W; Zhou M
    Urology; 2007 Aug; 70(2):385-90. PubMed ID: 17826525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles.
    Govindarajan A; Salgia NJ; Li H; Castro DV; Mirzapoiazova T; Armstrong B; Zhao D; Mercier BD; Dizman N; Chawla N; Zengin Z; Meza L; Tripathi N; Sayegh N; Chehrazi-Raffle A; Tripathi A; Pal SK
    Front Immunol; 2023; 14():1182581. PubMed ID: 37638025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
    Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
    Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study.
    Erlmeier F; Steffens S; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Ivanyi P;
    Clin Genitourin Cancer; 2021 Feb; 19(1):53-59.e1. PubMed ID: 32778505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of nectin-4 in papillary renal cell carcinoma.
    Zschäbitz S; Mikuteit M; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Duensing S; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Erlmeier F; Steffens S
    Discov Oncol; 2022 Sep; 13(1):90. PubMed ID: 36136143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular Expression of Prostate-specific Membrane Antigen (PSMA) in MiTF Family Translocation Renal Cell Carcinoma and Related Neoplasms.
    Baraban EG; Ged Y; Singla N; Allaf ME; Gorin MA; Markowski MC; Rowe SP; Argani P
    Appl Immunohistochem Mol Morphol; 2023 Sep; 31(8):544-549. PubMed ID: 37471632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease.
    Wagener N; Edelmann D; Benner A; Zigeuner R; Borgmann H; Wolff I; Krabbe LM; Musquera M; Dell'Oglio P; Capitanio U; Klatte T; Cindolo L; May M; Brookman-May SD;
    PLoS One; 2017; 12(9):e0184173. PubMed ID: 28934212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis.
    Chen LX; Zou SJ; Li D; Zhou JY; Cheng ZT; Zhao J; Zhu YL; Kuang D; Zhu XH
    World J Gastroenterol; 2020 Dec; 26(48):7664-7678. PubMed ID: 33505143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review of Papillary Renal Cell Carcinoma and MET Inhibitors.
    Rhoades Smith KE; Bilen MA
    Kidney Cancer; 2019 Nov; 3(3):151-161. PubMed ID: 31867475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.
    Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M
    BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole lesion quantitative CT evaluation of renal cell carcinoma: differentiation of clear cell from papillary renal cell carcinoma.
    Chen F; Huhdanpaa H; Desai B; Hwang D; Cen S; Sherrod A; Bernhard JC; Desai M; Gill I; Duddalwar V
    Springerplus; 2015; 4():66. PubMed ID: 25694862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Papillary vs clear cell renal cell carcinoma. Differentiation and grading by iodine concentration using DECT-correlation with microvascular density.
    Marcon J; Graser A; Horst D; Casuscelli J; Spek A; Stief CG; Reiser MF; Rübenthaler J; Buchner A; Staehler M
    Eur Radiol; 2020 Jan; 30(1):1-10. PubMed ID: 31278580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelin axis expression is markedly different in the two main subtypes of renal cell carcinoma.
    Douglas ML; Richardson MM; Nicol DL
    Cancer; 2004 May; 100(10):2118-24. PubMed ID: 15139053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Incidence and long-term prognosis of papillary renal cancer. Results of a retrospective multicenter study].
    Waalkes S; Roos FC; Eggers H; Schumacher S; Janssen M; Wegener G; Thüroff JW; Hofmann R; Schrader M; Kuczyk MA; Schrader AJ;
    Urologe A; 2011 Sep; 50(9):1125-9. PubMed ID: 21845424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma.
    Chang SS; Reuter VE; Heston WD; Gaudin PB
    Urology; 2001 Jun; 57(6):1179-83. PubMed ID: 11377343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.
    Pal SK; Ali SM; Yakirevich E; Geynisman DM; Karam JA; Elvin JA; Frampton GM; Huang X; Lin DI; Rosenzweig M; Lipson D; Stephens PJ; Ross JS; Miller VA; Agarwal N; Shuch B; Choueiri TK; Chung JH
    Eur Urol; 2018 Jan; 73(1):71-78. PubMed ID: 28592388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor grade estımatıon of clear cell and papıllary renal cell carcınomas usıng contrast-enhanced MDCT and FSE T2 weıghted MR ımagıng: radıology-pathology correlatıon.
    Halefoglu AM; Ozagari AA
    Radiol Med; 2021 Sep; 126(9):1139-1148. PubMed ID: 34100169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.